2021 annual financial data
Karyopharm Therapeutics 2021 Operating cash flow margin
Direct answer
Operating cash flow margin was -51.05%.
Operating income was -98,271,000 USD and net income was -124,088,000 USD.
Operating cash flow was -107,116,000 USD.
Get free Karyopharm Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 209,819,000 USD
- Operating income
- -98,271,000 USD
- Net income
- -124,088,000 USD
- Operating cash flow
- -107,116,000 USD